Abstract | BACKGROUND: Increased knowledge of the molecular regulatory mechanisms that contribute to the pathogenesis of psoriasis and other inflammatory diseases has created new opportunities for the development of targeted drug therapy for inflammatory conditions. Two new oral medications, apremilast and tofacitinib, have been developed for their immunomodulatory properties, and their potential efficacy in treating psoriasis is being evaluated. METHODS: RESULTS: CONCLUSION:
|
Authors | Rachel McAndrew, Ethan Levin, John Koo |
Journal | Journal of drugs in dermatology : JDD
(J Drugs Dermatol)
Vol. 14
Issue 8
Pg. 786-92
(Aug 2015)
ISSN: 1545-9616 [Print] United States |
PMID | 26267722
(Publication Type: Journal Article, Review)
|
Chemical References |
- Immunologic Factors
- Phosphodiesterase 4 Inhibitors
- Piperidines
- Protein Kinase Inhibitors
- Pyrimidines
- Pyrroles
- Thalidomide
- tofacitinib
- apremilast
|
Topics |
- Administration, Oral
- Clinical Trials, Phase III as Topic
- Humans
- Immunologic Factors
(therapeutic use)
- Phosphodiesterase 4 Inhibitors
(therapeutic use)
- Piperidines
(therapeutic use)
- Protein Kinase Inhibitors
(therapeutic use)
- Psoriasis
(drug therapy)
- Pyrimidines
(therapeutic use)
- Pyrroles
(therapeutic use)
- Randomized Controlled Trials as Topic
- Severity of Illness Index
- Thalidomide
(analogs & derivatives, therapeutic use)
|